Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Biotech Pharmaceutical

Status and phase: Completed; Phase 2; Phase 1

Conditions: Colorectal Cancer

Treatments: Drug: Nimotuzumab; Drug: Irinotecan

Study type: Interventional

Funder types: Other

Identifiers

NCT05278728

BT-CRC-T

Details and patient eligibility

About

Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety, and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy in patients with advanced colorectal cancer.

Full description

Nimotuzumab and Irinotecan will be administered to the patient until disease progression or development of toxicity preclude further treatment. Irinotecan will be administered once every 14 days, the dosage is 180mg/m2; Nimotuzumab treatment be divided 3 levels: 200mg/w, 400mg/w, 600mg/w, weekly. The patients'blood test and liver and renal function tests will be monitored weekly, a physical exam and reassessment of the tumor will be performed and every 6 weeks, when the total result is the CR or PR, the result of the 6th and the 12th week should be compared.

Enrollment: 31 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent form signed before performing any of the study's specific procedures.
• ECOG performance status 0-2.
• Age > 18，both genders.
• Metastatic colorectal cancer confirmed by pathology, or locally advanced unresectable colorectal cancer, or postoperative recurrence and metastasis colorectal cancer
• Disease progression after receiving oxaliplatin ± fluorouracil in first-line treatment
• At least 1 measurable lesions ,( longest diameter≥ 1 cm by spiral computed tomography (CT) scan or MRI)
• Life expectancy more than 3 months.
• K-ras is wild type
• Use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy.
• Liver metastasis, lesions smaller than 50% of the liver; Lung metastasis, lesions smaller than 30% of the lung
• Haemoglobin≥90g/L , granulocyte≥1.5×109/L ,WBC ≥3×109/L, platelet count≥100×109/L
• TBIL≤ 1.5 x ULN ,ALK≤ 2.5 x ULN or ≤ 5ULN（Liver metastasis），AST and ALT≤ 2.5 x ULN or ≤ 5ULN（Liver metastasis）,Creatinine ≤ 1.5 x ULN
• No brain metastasis

Exclusion criteria

• Previous radiotherapy at lesions within three months
• Other first line chemo-agents treatment except oxaliplatin ± fluorouracil
• Received other anti EGFR monoclonal antibody treatment
• Complete or incomplete intestinal obstruction
• Participation in other interventional clinical trials within 1 month
• Psychiatric disease affected cognitive ability, including brain metastasis
• Peripheral neuropathy lesion is more than I stage.
• History of serious allergic or allergy
• Pregnant or breast-feeding women
• Patients with the history of Serious lung or hear disease
• Other malignant tumor

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

31 participants in 1 patient group

Nimotuzumab and Irinotecan

Experimental group

Description:

Nimotuzumab： 200, 400, 600 or 800mg weekly until progression or AEs Irinotecan：180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles

Treatment:

Drug: Irinotecan

Drug: Nimotuzumab